Categories: Market Research

Melanoma Therapeutics Market Forecast 2024-2033: Growth Rate, Drivers, And Trends| AstraZeneca PLC, Bristol-Myers Squibb Co., Eli Lilly and Company, Merck & Co. Inc., Novartis AG

The Melanoma Therapeutics Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Melanoma Therapeutics Market:
https://www.thebusinessresearchcompany.com/report/melanoma-therapeutics-global-market-report

According to The Business Research Company’s Melanoma Therapeutics Global Market Report 2024, The melanoma therapeutics market size has grown rapidly in recent years. It will grow from $3.67 billion in 2023 to $4.1 billion in 2024 at a compound annual growth rate (CAGR) of 11.6%. The growth in the historic period can be attributed to shift in treatment guidelines, increased awareness and early detection, regulatory approvals and clinical trials, evolution of combination therapies, advancements in surgical techniques.

The melanoma therapeutics market size is expected to see rapid growth in the next few years. It will grow to $6.16 billion in 2028 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to emerging treatment modalities, biomarker identification, regulatory support for innovation, advancements in personalized medicine, immunotherapy enhancements. Major trends in the forecast period include evolving treatment guidelines, telemedicine in oncology, patient advocacy and awareness, biomarker research, combination therapies.

The increasing incidence of melanoma is expected to propel the growth of the melanoma therapeutics market going forward. Melanoma refers to a skin cancer that originates from melanocytes. Melanoma therapeutics are the therapies and drugs used to treat melanoma patients to alleviate cancer. Thus, the increasing incidence of melanoma boosts the sales of melanoma therapeutics. For instance, in May 2022, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, around 57,000 melanoma deaths and 325,000 new cases of the illness were expected to occur globally in 2020. Moreover, according to IARC (International Agency for Research on Cancer) scientists, cutaneous melanoma instances will rise by more than 50% to more than 500 000 cases annually, and melanoma-related deaths will increase by more than two-thirds to almost 100,000 cases annually between 2020 and 2040. Therefore, the increasing incidence of melanoma is driving the growth of the melanoma therapeutics drug market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=10713&type=smp

The melanoma therapeutics market covered in this report is segmented –

1) By Drug Type: Monoclonal Antibodies, Small Molecule Inhibitors, Other Drug Types
2) By Therapy: Surgery, Radiation Therapy, Immunotherapy, Targeted Therapy, Chemotherapy
3) By Route of administration: Oral, Injectable
4) By Cancer Type: Superficial Spreading Melanoma, Nodular Melanoma, Lentigno Maligna Melanoma, Acral Lentiginous Melanoma, Amelanotic Melanoma, Other Cancer Types
5) By Diagnosis: Dermatoscopy, Entinel Lymph Node Biopsy, Blood Test, X-ray, Ultrasound, CT Scan

Product innovations have emerged as a key trend gaining popularity in the melanoma therapeutics market. Major companies operating in the melanoma therapeutics market are developing new and innovative therapies to strengthen their position in the market. For instance, in January 2022, Immunocore, a UK-based biotechnology company, developed KIMMTRAK (tebentafusp-tebn) and received approval from the FDA to treat metastatic uveal melanoma. KIMMTRAK is the first and only therapy approved for treating unresectable or metastatic uveal melanoma after a successful phase 3 clinical trial clinically demonstrated an overall survival of almost 22 months. It is a brand-new bispecific protein with anti-CD3 immune-effector activity linked to a soluble T cell receptor. This is the first compound created with Immunocore’s ImmTAC technology platform that aims to reroute and activate T lymphocytes so they can identify and eliminate tumor cells.

The melanoma therapeutics market report table of contents includes:

1. Executive Summary
2.Melanoma Therapeutics Market Characteristics
3.Melanoma Therapeutics Market Trends And Strategies
4.Melanoma Therapeutics Market analysis
5.Melanoma Therapeutics Market Size And Growth
6.Melanoma Therapeutics Segmentation
7. Melanoma Therapeutics Regional And Country Analysis
.
.
.
27. Melanoma Therapeutics Competitive Landscape And Company Profiles
28.Melanoma Therapeutics Key Mergers And Acquisitions
29. Melanoma Therapeutics Future Outlook and Potential Analysis

TOP MAJOR PLAYERS:

AstraZeneca PLC
Bristol-Myers Squibb Co.
Eli Lilly and Company
Merck & Co. Inc.
Novartis AG
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293